Basic Information
LncRNA/CircRNA Name | lncRNA-ATB |
Synonyms | LOC109207222 |
Region | NA |
Ensemble | NA |
Refseq | NA |
Classification Information
Regulatory Mechanism | Biological Function | Clinical Application | |||
---|---|---|---|---|---|
TF | Immune | Survival | |||
Enhancer | Apoptosis | Drug | |||
Variant | Cell Growth | Circulating | |||
MiRNA | EMT | Metastasis | |||
Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
Cancer Name | esophageal squamous cell carcinoma |
ICD-0-3 | NA |
Methods | qPCR, Western blot, Luciferase reporter assay, RIP etc. |
Sample | esophageal squamous cell carcinoma tissues, cell lines (KYSE150, KYSE140, KYSE410, KYSE520, KYSE510, Ec109, Ec9706 and KYSE30) |
Expression Pattern | up-regulated |
Function Description | Upregulated lnc-ATB served as an independent prognosis predictor of ESCC patients. Moreover, loss-of-function assays in ESCC cells showed that knockdown of lnc-ATB inhibited cell proliferation and migration both in vitro and in vivo. Mechanistic investigation indicated that lnc-ATB exerted oncogenic activities via regulating Kindlin-2, as the anti-migration role of lnc-ATB silence was attenuated by ectopic expression of Kindlin-2. Further analysis showed that lnc-ATB functions as a molecular sponge for miR-200b and Kindlin-2. Dysregulated miR-200b/Kindlin-2 signaling mediated the oncogenic activity of lnc-ATB in ESCC. Our results suggest that lnc-ATB predicts poor prognosis and may serve as a potential therapeutic target for ESCC patients. The results showed that the median overall survival of patients with high lnc-ATB expression was 20 months, whereas the median overall survival for patients with low lnc-ATB expression was 51 months. |
Pubmed ID | 28640252 |
Year | 2017 |
Title | Long non-coding RNA ATB promotes malignancy of esophageal squamous cell carcinoma by regulating miR-200b/Kindlin-2 axis. |
External Links
Links for lncRNA-ATB | GenBank HGNC NONCODE |
Links for esophageal squamous cell carcinoma | OMIM COSMIC |